CRISPR/Cas9 genome editing of CCR5 combined with C46 HIV-1 fusion inhibitor for cellular resistant to R5 and X4 tropic HIV-1
Authors:
Open Access
- 13 May 2024
- journal article
- research article
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-13
Abstract
Hematopoietic stem-cell (HSC) transplantation using a donor with a homozygous mutation in the HIV co-receptor CCR5 (CCR5Δ32/Δ32) holds great promise as a cure for HIV-1. Previously, there were three patients that had been reported to be completely cured from HIV infection by this approach. However, finding a naturally suitable Human Leukocyte Antigen (HLA)-matched homozygous CCR5Δ32 donor is very difficult. The prevalence of this allele is only 1% in the Caucasian population. Therefore, additional sources of CCR5Δ32/Δ32 HSCs are required. The Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated (Cas) system is one method to mediate CCR5 knockout in HSCs that has been successfully employed as a gene editing tool in clinical trials. Additional anti-HIV-1 strategies are still required for broad-spectrum inhibition of HIV-1 replication. Here in this study, we combined an additional anti-HIV-1 therapy, which is C46, a cell membrane-anchored HIV-1 fusion inhibitor with the CRISPR/Cas9 mediated knockout CCR5. The combined HIV-1 therapeutic genes were investigated for the potential prevention of both CCR5 (R5)- and CXCR4 (X4)-tropic HIV-1 infections in the MT4CCR5 cell line. The combinatorial CRISPR/Cas9 therapies were superior compared to single method therapy for achieving the HIV-1 cure strategy and shows potential for future applications.Keywords
Funding Information
- Office of National Higher Education Science Research and Innovation Policy Council through the Program Management Unit for Human Resources & Institutional Development, Research and Innovation (B05F630063)
- King Mongkut’s Institute of Technology Ladkrabang (2563–0216006)
- Mahidol University
This publication has 54 references indexed in Scilit:
- Inhibition of Human Immunodeficiency Virus Type 1 Entry in Cells Expressing gp41-Derived PeptidesJournal of Virology, 2004
- The CCR5 and CXCR4 Coreceptors—Central to Understanding the Transmission and Pathogenesis of Human Immunodeficiency Virus Type 1 InfectionAIDS Research and Human Retroviruses, 2004
- Methylguanine methyltransferase–mediated in vivo selection and chemoprotection of allogeneic stem cells in a large-animal modelJournal of Clinical Investigation, 2003
- Lentivirus Vector Purification Using Anion Exchange HPLC Leads to Improved Gene TransferBioTechniques, 2003
- Inhibiting HIV-1 infection in human T cells by lentiviral-mediated delivery of small interfering RNA against CCR5Proceedings of the National Academy of Sciences, 2002
- Design of HIV Vectors for Efficient Gene Delivery into Human Hematopoietic CellsMolecular Therapy, 2002
- Global distribution of the CCR5 gene 32-basepair deletionNature Genetics, 1997
- Expression of human alpha 1-antitrypsin in dogs after autologous transplantation of retroviral transduced hepatocytes.Proceedings of the National Academy of Sciences, 1992
- Promoter-regulatory region of the major immediate early gene of human cytomegalovirus.Proceedings of the National Academy of Sciences, 1984
- Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphomaProceedings of the National Academy of Sciences of the United States of America, 1980